Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factors
Jingjing Jiao, Gordon P. Watt, Heather L. Stevenson, Tiffany L. Calderone, Susan P. Fisher‐Hoch, Yuanqing Ye, Xifeng Wu, John M. Vierling, Laura Beretta – 27 April 2018 – Telomerase reverse transcriptase (TERT) mutation is the most frequent genetic alteration in hepatocellular carcinoma (HCC). Our aims were to investigate whether TERT mutations can be detected in circulating cell‐free DNA (cfDNA) of patients with HCC and/or cirrhosis and characterize clinical parameters associated with these mutations.